CAR-T细胞治疗实体瘤的挑战与思考

发布时间：2018-05-05 21:22

本文选题：嵌合抗原受体T细胞 + 实体肿瘤　；参考：《中国肿瘤临床》2017年09期

【摘要】：针对CD19靶点的嵌合抗原受体(chimeric antigen receptor,CAR)T细胞在B细胞恶性血液系统肿瘤治疗中取得的成功,证实了抗原特异性靶向免疫细胞对肿瘤治疗的临床价值。同时这一发现也激发了CAR-T细胞技术的拓展应用性研究,多项CART细胞治疗实体瘤的临床前研究和临床研究正在开展。然而实体肿瘤和血液肿瘤本身特质上的差异决定了这种治疗模式必须重新斟酌细胞治疗本身的特点、作用规律等因素。本文讨论了CAR-T细胞治疗实体瘤相关的安全性管控措施、肿瘤靶点选择、预处理及联合治疗,并通过相关的实践经验展望该治疗方式的未来发展方向。
[Abstract]:The success of chimeric antigen receptor CART cells targeting CD19 targets in the treatment of malignant hematopoietic tumors of B cells has confirmed the clinical value of antigen-specific immunocytes in the treatment of tumors. At the same time, this discovery has stimulated the extensive application of CAR-T cell technology, and many preclinical and clinical studies of CART cell therapy for solid tumors are being carried out. However, the difference between solid tumor and blood tumor determines that this treatment mode must reconsider the characteristics and action rules of cell therapy itself. In this paper, the safety control measures, tumor target selection, preconditioning and combined therapy for solid tumor treated by CAR-T cells are discussed, and the future development of this treatment method is prospected through relevant practical experience.
【作者单位】：解放军总医院生命科学院生物治疗病区;解放军总医院老年血液科;
【分类号】：R730.51

【相似文献】